BioSpace News Archive

Urology of Virginia, has enrolled their first patient in the VESAIR Clinical Trial. The VESAIR Clinical Trial is being conducted in several distinguished clinics throughout the US to test the safety and efficacy of the Vesair Bladder Control Balloon procedure.

180 Life Sciences Corp., a clinical-stage biotechnology company with its lead indication in Phase 2b/3, focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, announced the continued expansion of its IP portfolio.

Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced plans to report data presentations highlighting the medical needs in systemic mastocytosis (SM) and the broad potential of AYVAKIT™ (avapritinib) across multi

The Progeria Research Foundation announced that it will receive half of the net proceeds of the sale of a Priority Review Voucher.

Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced Sekar Kathiresan, M.D., co-founder and chief executive officer, will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference taking place November 30-December 3, 2020.

Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference

PainReform Ltd., a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, announced the appointment of Ilan Hadar as Chief Executive Officer.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces clinical and regulatory progress by multiple partners utilizing antibodies from its OmniAb® discovery platform.

Hancock Jaffe Laboratories, Inc., a developer of medical devices that restore cardiac and vascular health, announced that the Journal of Vascular Surgery Venous and Lymphatic Disorders, published a paper featuring interim results from the VenoValve first-in-human trial.